Cargando…

Transcriptome Alteration in the Diabetic Heart by Rosiglitazone: Implications for Cardiovascular Mortality

BACKGROUND: Recently, the type 2 diabetes medication, rosiglitazone, has come under scrutiny for possibly increasing the risk of cardiac disease and death. To investigate the effects of rosiglitazone on the diabetic heart, we performed cardiac transcriptional profiling and imaging studies of a murin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilson, Kitchener D., Li, Zongjin, Wagner, Roger, Yue, Patrick, Tsao, Phillip, Nestorova, Gergana, Huang, Mei, Hirschberg, David L., Yock, Paul G., Quertermous, Thomas, Wu, Joseph C.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2481284/ https://www.ncbi.nlm.nih.gov/pubmed/18648539 http://dx.doi.org/10.1371/journal.pone.0002609

Ejemplares similares

Biosensor Development and Innovation in Healthcare and Medical Applications
por: Mills, David K., et al.
Publicado: (2023)

Leukemia and rosiglitazone
por: Yavasoglu, Irfan, et al.
Publicado: (2016)

Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial
por: Florez, H, et al.
Publicado: (2015)

The Janus face of rosiglitazone
por: Pich, Christine, et al.
Publicado: (2018)

Rosiglitazone and Pioglitazone Alter Aromatase Kinetic Properties in Human Granulosa Cells
por: Araki, Takako, et al.
Publicado: (2011)

Advances in Biosensors Technology for Detection and Characterization of Extracellular Vesicles
por: Ishraq Bari, Saif Mohammad, et al.
Publicado: (2021)

Identification of microRNA-mRNA regulatory network associated with oxidative DNA damage in human astrocytes
por: Nwokwu, Chukwumaobim Daniel, et al.
Publicado: (2022)

Rosiglitazone Regulates Anti-Inflammation and Growth Inhibition via PTEN
por: Lin, Chiou-Feng, et al.
Publicado: (2014)

Transcriptomic profiling of the telomerase transformed Mesenchymal stromal cells derived adipocytes in response to rosiglitazone
por: Al-Ali, Moza Mohamed, et al.
Publicado: (2022)

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study
por: Juurlink, David N, et al.
Publicado: (2009)

Prenatal Rosiglitazone Administration to Neonatal Rat Pups Does Not Alter the Adult Metabolic Phenotype
por: Sierra, Hernan, et al.
Publicado: (2012)

Altered Expression of Long Noncoding and Messenger RNAs in Diabetic Nephropathy following Treatment with Rosiglitazone
por: Zhang, Liwen, et al.
Publicado: (2020)

Rosiglitazone and Fenofibrate Additive Effects on Lipids
por: Slim, Ahmad, et al.
Publicado: (2011)

Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPARγ-driven enhancers
por: Step, Sonia E., et al.
Publicado: (2014)

Preparation and in vitro evaluation of enteric-coated tablets of rosiglitazone sodium
por: Pan, Xin-mei, et al.
Publicado: (2015)

Persistent Donor Cell Gene Expression among Human Induced Pluripotent Stem Cells Contributes to Differences with Human Embryonic Stem Cells
por: Ghosh, Zhumur, et al.
Publicado: (2010)

Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance
por: Varghese, Anitha, et al.
Publicado: (2009)

Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review
por: Wang, Amy T, et al.
Publicado: (2010)

PLA-PEG Nanoparticles Improve the Anti-Inflammatory Effect of Rosiglitazone on Macrophages by Enhancing Drug Uptake Compared to Free Rosiglitazone
por: Giacalone, Giovanna, et al.
Publicado: (2018)

Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal
Publicado: (2011)

Safety and efficacy of rosiglitazone in the elderly diabetic patient
por: Viljoen, Adie, et al.
Publicado: (2009)

Effect and cardiovascular safety of adding rosiglitazone to insulin therapy in type 2 diabetes: A meta-analysis
por: Lu, Yu, et al.
Publicado: (2015)

Antitumor action of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone in hepatocellular carcinoma
por: BO, QI-FU, et al.
Publicado: (2015)

Evaluation of in-stent restenosis in the APPROACH trial (assessment on the prevention of progression by Rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history)
por: García-García, Héctor M., et al.
Publicado: (2011)

Candidate genes associated with the effect of rosiglitazone on glycemic control and cardiovascular system in the treatment of type 2 diabetes mellitus
por: Wu, Xiaoli
Publicado: (2019)

Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses
por: Wallach, Joshua D, et al.
Publicado: (2020)

Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses
Publicado: (2021)

Simpson's paradox visualized: The example of the Rosiglitazone meta-analysis
por: Rücker, Gerta, et al.
Publicado: (2008)

A phase II trial with rosiglitazone in liposarcoma patients
por: Debrock, G, et al.
Publicado: (2003)

Rosiglitazone as an option for patients with acromegaly: a case series
por: Tamez-Pérez, Héctor E, et al.
Publicado: (2011)

In vivo effects of rosiglitazone in a human neuroblastoma xenograft
por: Cellai, I, et al.
Publicado: (2010)

Rosiglitazone and Myocardial Infarction in Patients Previously Prescribed Metformin
por: Dormuth, Colin R., et al.
Publicado: (2009)

Rosiglitazone activation of PPARγ suppresses fractalkine signaling
por: Wan, Yihong, et al.
Publicado: (2010)

Treatment of diabetic vasculopathy with rosiglitazone and ramipril: Hype or hope?
por: Rahman, Sayeeda, et al.
Publicado: (2009)

Interactions of Rosiglitazone and Anti-Arrhythmic Drugs in Animal Model
por: Mohammed, YM, et al.
Publicado: (2012)

Topical Rosiglitazone Is an Effective Anti-Scarring Agent in the Cornea
por: Huxlin, Krystel R., et al.
Publicado: (2013)

Restoring adiponectin via rosiglitazone ameliorates tissue wasting in mice with lung cancer
por: Langer, Henning Tim, et al.
Publicado: (2023)

Antineoplastic effects of rosiglitazone and PPARγ transactivation in neuroblastoma cells
por: Cellai, I, et al.
Publicado: (2006)

Rosiglitazone RECORD study: glucose control outcomes at 18 months
por: Home, P D, et al.
Publicado: (2007)

Impact of rosiglitazone meta-analysis on use of glucose-lowering medications
por: Morrow, Richard L, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_fr7hr3lo2gt9dukjj97j6tu2gm